The five-year investment plan focuses on upgrading critical production infrastructure at the site, which serves as a core hub for active pharmaceutical ingredients. By refreshing key machinery and operational capacity, the company intends to insulate its drug substance manufacturing against international supply disruptions while scaling up for U.S. clients. This move underscores a broader industry shift toward regionalizing production to mitigate risks associated with volatile global trade environments.